Bone Health Management in the Continuum of Prostate Cancer Disease

Area of Science:

• Oncology
• Urology
• Bone Metastasis Research

Background:

• Prostate cancer (PCa) is a leading cause of cancer death in men, driven by androgen receptor (AR) signaling.
• Androgen deprivation therapy (ADT) is standard for advanced PCa, but often leads to metastatic castration-resistant prostate cancer (mCRPC).
• Bone metastases are prevalent in mCRPC, significantly impacting patient survival and quality of life.

Purpose of the Study:

• To review the pathogenesis of PCa-induced bone metastasis.
• To discuss the impact of metastatic PCa on bone health and vital organs.
• To examine current and future therapeutic strategies for bone metastasis and skeletal-related events in prostate cancer.

Main Methods:

• Literature review of pathogenesis, diagnostics, and treatments for PCa bone metastasis.
• Analysis of current interventions including bisphosphonates, immunotherapy, and radiation therapy.
• Exploration of emerging and future therapeutic targets for bone management.

Main Results:

• PCa bone metastases are a significant cause of morbidity and mortality in mCRPC patients.
• Existing diagnostic and treatment modalities for bone metastases have limitations in efficacy.
• Advanced imaging detects early bone changes, but effective management remains challenging.

Conclusions:

• Understanding PCa bone metastasis pathogenesis is crucial for developing better treatments.
• There is a critical need for more effective therapies to manage bone metastases and skeletal-related events.
• Future research should focus on novel therapeutic options to improve bone health and survival in advanced prostate cancer.